Aligos Therapeutics Presents Data At The AASLD Liver Meeting 2023 Demonstrating That Treatment With ALG-000184 Results In Significant Multi-Log Reductions In Hepatitis B Antigens
Portfolio Pulse from Benzinga Newsdesk
Aligos Therapeutics has presented data at the AASLD Liver Meeting 2023 showing that treatment with ALG-000184 results in significant reductions in Hepatitis B antigens. The data suggests that ALG-000184 may lower cccDNA levels via both mechanisms of action for CAM-E drugs and has a well-tolerated safety profile.
November 10, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aligos Therapeutics' ALG-000184 has shown promising results in reducing Hepatitis B antigens, which could potentially boost the company's stock in the short term.
The positive results from the ALG-000184 treatment could potentially lead to increased investor confidence in Aligos Therapeutics, leading to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100